BHCM
CRNX icon

Brevan Howard Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Brevan Howard Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,969
Closed -$499K – 1887
2025
Q3 		$499K Buy
+11,969
New +$383K ﹤0.01% 1295
2025
Q1 		– Sell
-9,777
Closed -$500K – 1209
2024
Q4 		$500K Buy
+9,777
New +$547K ﹤0.01% 621

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Brevan Howard Capital Management's CRNX Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 11,969 shares — an estimated $499K sold.

Brevan Howard Capital Management first reported a position in CRNX in Q4 2024 and held it in 2 quarters. The position peaked at $500K in Q4 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 11,969 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $499K.
  • Brevan Howard Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Brevan Howard Capital Management's Crinetics Pharmaceuticals position peaked at $500K in Q4 2024.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.